Combined use of bispecific antibody binding to activated coagulation factor ix and coagulation factor x with blood coagulation factor x for treating subject with hemophilia a
AssigneesPublic University Corporation Nara Medical University, KM Biologics Co., Ltd.
InventorsKeiji NOGAMI, Yuto NAKAJIMA, Kazuki SHIMIZU, Eisuke TAKAMI, Hirotoshi NAKANO
Life of this patent
Estimating the term…
Abstract
Provided is a pharmaceutical composition comprising blood coagulation Factor X for treating a subject with hemophilia A. The present invention relates to a pharmaceutical composition comprising blood coagulation Factor X for treating a subject with hemophilia A, wherein the blood coagulation Factor X is used in combination with a bispecific antibody binding to activated blood coagulation Factor IX and blood coagulation Factor X.
Claims10
1-4. (canceled)
A method of treating hemophilia A in a subject in need thereof, comprising administering to the subject blood coagulation Factor X in combination with a bispecific antibody that binds to activated blood coagulation Factor IX and blood coagulation Factor X.
Dependencies are inferred from the claim text.